Specific parameters, including the tumor microenvironment, immune cells, immune checkpoint molecules, BRCA1/2 mutations, genetic oncology, and prognosis, help identify patients eligible for immunotherapy [45]. This evidence concerns the gene BRCA1 and neoplasm.